• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.15
  • VXN 19.51
  • VXO 16.03
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

Last Trade Dividend/Share PE Ratio
Date Dividend Yield Return on Assets
Change ExDividend Date Return on Capital
Bid Latest EPS Price/Sale
Ask LatestEPS Date Price to Book
Volume EPS ttm Institutional %
Avg Volume Shares Outstanding Insider %
Open Float Short Ratio
Prev Close Return On Equity 5 Year Change %
High Consensus EPS 2 Year Change %
Low No. of Estimate 1 Year Change %
52 Week High EPS Surprise $ YTD Change %
52 Week Low EPS Surprise Percent 6 Month Change %
52 Week Change EBITDA 3 Month Change %
50 Day MA Revenue 1 Month Change %
200 Day MA Gross Profit 5 Day Change %
Market Cap Cash 30 Day Change %
Beta Debt Stock Exchange
Sector Revenue Per Share Short Interest
Short Date Revenue Per Employee Short Ratio
Data courtesy of IEX
Company Profile

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction, and other unmet medical needs in the United States. Its drug candidates in Phase II clinical trials include Archexin, the lead anticancer drug candidate is an inhibitor of the protein kinase Akt for the treatment of pancreatic cancer and renal cell carcinoma; Serdaxin for the treatment of depression and neurodegenerative disorders; and Zoraxel, a drug for sexual dysfunction that modulates the sexual activity control center in the brain. Its pre-clinical pipeline products include RX-1792, a molecule targeted anticancer drug candidate; RX-5902, a molecule microtubule inhibitor anticancer drug candidate; RX-3117, a molecule anti-metabolite nucleoside anticancer drug candidate; RX-8243, a molecule aurora kinase inhibitor anticancer drug candidate; RX-0201-Nano, nanoliposomal anticancer Akt-1 inhibitor; RX-0047-Nano, nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101 & RX-21202, a nano-polymer anticancer. The company has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; TheraTarget, Inc.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; and Revaax Pharmaceuticals LLC. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.